Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 18/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19639768 | 0.99 | ELANE (0.44) | ELANECTSKPDE4BPDE4D | |
| Benzene SCHEMBL19639750 | 0.99 | ELANE (0.44) | ELANECTSK | |
| SCHEMBL19639796 | 0.97 | ELANE (0.46) | ELANEPDE4BPDE4D | |
| Benzene SCHEMBL19639816 | 0.97 | ELANE (0.45) | ELANEPDE4BPDE4D | |
| SCHEMBL19639756 | 0.94 | ELANE (0.41) | ELANECTSK | |
| SCHEMBL19688323 | 0.92 | ELANE (0.42) | ELANECTSK | |
| SCHEMBL19639828 | 0.92 | ELANE (0.44) | ELANECTSK | |
| Bromide SCHEMBL19639790 | 0.92 | ELANE (0.41) | ELANECTSK | |
| SCHEMBL19639749 | 0.90 | ELANE (0.47) | ELANE | |
| Benzene SCHEMBL19639826 | 0.89 | ELANE (0.46) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464269-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF A HNE RELATED DISEASE | CHIESI FARM SPA (IT) | 2020-04-01 | — | — | EP | claimed |
| US-9862706-B2 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-01-09 | — | — | US | disclosed |
| WO-2017207433-A1 | HETETOCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF A DISEASE IN WHICH HNE IS IMPLICATED | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-12-07 | — | — | WO | disclosed |
| US-20170342056-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342056-A1 | NOVEL COMPOUNDS | SERPINB1, ELANE, MPO | ELANE 2/4885CTSK 100/4885PDE4B 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.